Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2025-08-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司第五届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 9th meeting of the 5th Board of Directors of the company 辰欣药业股份有限公司. It includes information about the approval of the 2025 semi-annual report and its summary, profit distribution plan, amendments to the company charter and governance documents, and other corporate governance matters. The document also references that the full semi-annual report and other detailed announcements are disclosed separately on the Shanghai Stock Exchange website. The document is not the semi-annual report itself but a board meeting resolution announcement covering multiple governance and financial topics. It is not a full financial report (like an Interim/Quarterly Report) but a board/management information disclosure about decisions and governance changes. Therefore, the best fitting category is Board/Management Information (MANG). The document length (5392 characters) and content confirm it is a meeting resolution announcement rather than a full report or a simple report publication notice.
2025-08-27 Chinese
辰欣药业股份有限公司关于2025 年半年度利润分配方案的公告.docx
Notice of Dividend Amount Classification · 100% confidence The document is titled as a "2025 年半年度利润分配方案的公告" which translates to "Announcement of the 2025 Half-Year Profit Distribution Plan." It details the dividend amount per share, the total dividend payout, and the authorization process by the board and shareholders. The document is an announcement of the dividend distribution plan, including the decision-making process and approval by the board and supervisory committee. It does not contain comprehensive financial statements or detailed financial performance data typical of an Interim/Quarterly Report (IR). Instead, it focuses on the dividend amount and related shareholder approvals, which fits the definition of a Notice of Dividend Amount (DIV). The document length is 1323 characters, which is short and focused on dividend details, not a full financial report. Therefore, the correct classification is Notice of Dividend Amount (DIV).
2025-08-27 Chinese
辰欣药业股份有限公司关于2024年度“提质增效重回报”行动方案的评估报告暨2025年度“提质增效重回报”行动方案的公告
Management Reports Classification · 90% confidence The document is an announcement by the company 辰欣药业股份有限公司 regarding the evaluation report of the 2024年度“提质增效重回报”行动方案 and the 2025年度行动方案. It includes detailed operational and financial performance data for 2024, strategic plans for 2025, and shareholder return policies. The document is about the assessment and continuation of a specific action plan rather than a full annual or interim financial report. It is also not a simple announcement of a report being published but contains substantive content including financial figures, business strategy, and governance information. The document length is 4362 characters, which is relatively short but contains detailed content. It is not a certification or a brief announcement. The content aligns best with a Management Reports (MDA) filing, as it provides management's detailed explanation of financial results, business trends, and outlook related to a specific action plan and company strategy.
2025-08-27 Chinese
辰欣药业股份有限公司2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 Half-Year Report Summary' (半年度报告摘要) for the company 辰欣药业股份有限公司. It contains detailed financial data for the half-year period ending June 30, 2025, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and references the full report for comprehensive details. The length is 2915 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The document also includes a profit distribution plan for the half-year period. Given these characteristics, this document fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. It is not a mere announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. H1 2025
2025-08-27 Chinese
辰欣药业股份有限公司募集资金管理办法（2025年8月）
Regulatory Filings Classification · 95% confidence The document is titled '募集资金管理办法' which translates to 'Fundraising Capital Management Measures' and is issued by 辰欣药业股份有限公司 (Chenxin Pharmaceutical Co., Ltd.). It is a detailed internal policy document outlining the management, storage, usage, supervision, and change of use of funds raised by the company through stock issuance or other equity securities. The document references regulatory frameworks such as the Shanghai Stock Exchange listing rules and securities laws, and it includes detailed procedural and supervisory requirements for the use of raised funds. It is not a financial report, earnings release, or announcement of voting results. It is a regulatory compliance and internal control document related to capital management. It does not contain financial statements or earnings data, nor is it a report publication announcement. Therefore, it best fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory and compliance documents that do not fit other specific categories.
2025-08-27 Chinese
辰欣药业股份有限公司股东会议事规则（2025年8月）
Governance Information Classification · 95% confidence The document is titled as "股东会议事规则" which translates to "Shareholders Meeting Rules" for the company 辰欣药业股份有限公司. It details the procedures, powers, and regulations governing the shareholders' meetings, including the convening, proposal submission, voting procedures, and legal compliance. It is a governance document outlining internal rules and processes related to shareholder meetings rather than a report of financial results, audit, or announcements of voting results. It does not contain financial statements or earnings data, nor is it a notice or announcement of a meeting or results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (9681 characters) and detailed procedural content support this classification with high confidence.
2025-08-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.